ACRS News and Press, Aclaris Therapeutics Inc. From 08/05/21

Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024 Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in Moderate to Severe Atopic Dermatitis Announced in June Adva...

naphtalina/iStock via Getty Images Jefferies has assumed Aclaris Therapeutics ([[ACRS]] +0.9%) with a buy rating and has raised its price target to $32 from $27, implying a premium of ~105.0% as the analysts point to a key event linked to the company’s rheumatoid arthritis candidate AT...

WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will particip...

As the standard first-line treatment for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, naproxen and other NSAIDs are effective, but can induce ulceration and bleeding of the digestive tract, with much higher incidence in patients, as noted by An...

Aclaris Therapeutics (ACRS) has priced its public offering of 7,042,254 common shares at $17.75/share, for expected gross proceeds of ~$125M.Underwriters' over-allotment is an additional 1,056,338 shares.Closing date is June 14. Jefferies, SVB Leerink and Piper Sandler are acting as joint boo...

Yesterday, Aclaris Therapeutics ([[ACRS]] -8.4%) announced positive data from a Phase 2a study for its JAK inhibitor ATI-1777 in patients with moderate to severe atopic dermatitis ((AD)).The study achieved statistical significance with the primary endpoint of modified Eczema Area and Sev...

Gainers: Aethlon Medical AEMD +425%, Checkpoint Therapeutics CKPT +26%, Adamis Pharmaceuticals ADMP +12%, SCWorx (WORX) +18%, ZIOPHARM Oncology ZIOP +15%.Losers: Atossa Therapeutics ATOS -14%, CEL-SCI CVM -11%, Precipio (PR...

Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...

ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach ATI-1777 was Generally Well Tolerated Data Support Progression to Ph...

WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a...